AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26147818 — intervention group
Group type: EXPERIMENTAL
Intervention: DentalVibe Injection Comfort System (DV)
Number of subjects: 60
Study 26147818 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe (TS)
Number of subjects: 60
Study 24105455 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (Rapamune 2 mg/d) for 14 days
Number of subjects: 38
Study 22306103 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Aneurysm Repair (OR)
Number of subjects: 334
Study 22306103 — intervention group
Group type: COMPARATOR
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 334
Study 19470885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg
Number of subjects: 405
Study 19470885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 18089878 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem-cell transplant (SCT)
Number of subjects: 347
Study 18089878 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 347
Study 14981379 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of misoprostol with saline solution (group I, 41 women)
Number of subjects: 80
Study 14981379 — intervention group
Group type: COMPARATOR
Intervention: 800 microg of misoprostol without saline solution (group II, 39 women)
Number of subjects: 80
Study 11458251 — intervention group
Group type: EXPERIMENTAL
Intervention: Procosol sealer (PS)
Number of subjects: 204
Study 11458251 — intervention group
Group type: EXPERIMENTAL
Intervention: CRCS sealer (CR)
Number of subjects: 204
Study 11458251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealapex sealer (SA)
Number of subjects: 204
Study 9722720 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival plaque control and oral hygiene instruction
Number of subjects: 21
Study 9722720 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cerebral palsy patients)
Number of subjects: 21
Study 9722720 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline examination
Number of subjects: 21
Study 8822155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hints in the form of the analogues' themes
Number of subjects: 0
Study 8822155 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented training
Number of subjects: 0
Study 8822155 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-oriented training
Number of subjects: 0
Study 8822155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hints in the transfer phase
Number of subjects: 0
Study 8822155 — intervention group
Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 0
Study 1979615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg)
Number of subjects: 36
Study 1979615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 36
Study 1979615 — intervention group
Group type: COMPARATOR
Intervention: Both bisoprolol and nitrendipine
Number of subjects: 36
Study 1979615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 36
Study 1979615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 36
Study 6102235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (intercostal block by freezing technique)
Number of subjects: 15
Study 6102235 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics or no blockade (control group)
Number of subjects: 15
Study 30885012 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (EIN)
Number of subjects: 124
Study 30885012 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (SEN)
Number of subjects: 124
Study 30561562 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline 1 mg/kg every 12 hours for 4-14 days
Number of subjects: 400
Study 30561562 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 hours for 4-14 days
Number of subjects: 400
Study 30561562 — intervention group
Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 400
Study 30561562 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 400
Study 27716665 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (2 g/day)
Number of subjects: 240
Study 27716665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 240
Study 25935520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh human milk applied to eczema spots, three times a day for four weeks
Number of subjects: 9
Study 25935520 — intervention group
Group type: COMPARATOR
Intervention: Emollient applied to eczema spots, three times a day for four weeks
Number of subjects: 9
Study 25935520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh human milk applied to eczema spots
Number of subjects: 9
Study 25935520 — intervention group
Group type: COMPARATOR
Intervention: Emollient applied to eczema spots
Number of subjects: 9
Study 25935520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh human milk samples
Number of subjects: 9
Study 26491122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling (breastfeeding promotion and increased intake of micronutrient-rich and energy-dense foods)
Number of subjects: 363
Study 23382975 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (1 µg/ml)
Number of subjects: 43
Study 23382975 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (2 µg/ml)
Number of subjects: 43
Study 21450224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program (10 twice-weekly, 2-hour sessions with physical and psychological components and a booster session)
Number of subjects: 36
Study 21450224 — intervention group
Group type: COMPARATOR
Intervention: Usual geriatric care (control group)
Number of subjects: 36
Study 21450224 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Number of subjects: 36
Study 18342453 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 2.0 atmospheres absolute (Group 1)
Number of subjects: 150
Study 18342453 — intervention group
Group type: COMPARATOR
Intervention: Air at 1.1 atmospheres absolute (Group 2)
Number of subjects: 150
Study 16873760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (social inclusion program)
Number of subjects: 7594
Study 16873760 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 7594
Study 12845362 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain (Group A)
Number of subjects: 26
Study 12845362 — intervention group
Group type: COMPARATOR
Intervention: No suction drain (Group B)
Number of subjects: 26
Study 10831468 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse life events, sociotropy, and autonomy factor need for control
Number of subjects: 86
Study 10831468 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse interpersonal events (e.g., death of a loved one)
Number of subjects: 86
Study 10831468 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 86
Study 9876895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybritech Tandem‐E PSA assay
Number of subjects: 182
Study 8062496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronomodulated schedule (oxaliplatin at 4 pm, 5-fluorouracil and folinic acid at 4 am)
Number of subjects: 9
Study 8062496 — intervention group
Group type: COMPARATOR
Intervention: Constant rate schedule
Number of subjects: 9
Study 2526008 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg intravenous bolus
Number of subjects: 28
Study 5440545 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide
Number of subjects: 778
Study 5440545 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide
Number of subjects: 778
Study 5440545 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas and oxygen machine (50% oxygen and 50% nitrous oxide)
Number of subjects: 778
Study 30540548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption among student-athletes
Number of subjects: 670
Study 30540548 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective behavioral strategies (PBS)
Number of subjects: 670
Study 30540548 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-group gender differences in alcohol use and PBS
Number of subjects: 670
Study 31300507 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery at 6 months of age (Sommerlad technique)
Number of subjects: 600
Study 31300507 — intervention group
Group type: COMPARATOR
Intervention: Surgery at 12 months of age (Sommerlad technique)
Number of subjects: 600
Study 27820725 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic-style weightlifting (OWL)
Number of subjects: 39
Study 27820725 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized strength and power training (MSPT)
Number of subjects: 39
Study 27820725 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weight strength and power training (FSPT)
Number of subjects: 39
Study 24894344 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 327
Study 24894344 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (CERA)
Number of subjects: 327
Study 24894344 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa or beta
Number of subjects: 327
Study 24894344 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin
Number of subjects: 327
Study 24894344 — intervention group
Group type: EXPERIMENTAL
Intervention: CERA
Number of subjects: 327
Study 24894344 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 327
Study 24240244 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.5 mg levonorgestrel intrauterine contraceptive system
Number of subjects: 2884
Study 24240244 — intervention group
Group type: EXPERIMENTAL
Intervention: 19.5 mg levonorgestrel intrauterine contraceptive system
Number of subjects: 2884
Study 21620765 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients (N=20)
Number of subjects: 38
Study 21620765 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=18)
Number of subjects: 38
Study 18081728 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGBP)
Number of subjects: 42
Study 16506273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d)
Number of subjects: 68
Study 16506273 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg/d)
Number of subjects: 68
Study 16506273 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.6 mg/d)
Number of subjects: 68
Study 16506273 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (270 mg/d)
Number of subjects: 68
Study 12672168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol received (0.5 g/kg)
Number of subjects: 0
Study 12672168 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol received (0.5 g/kg) with expectancy of alcohol (2-3 standard drinks)
Number of subjects: 0
Study 12672168 — intervention group
Group type: COMPARATOR
Intervention: No alcohol received (0.0 g/kg) and no expectancy
Number of subjects: 0
Study 11196347 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg/day of anapsos
Number of subjects: 45
Study 11196347 — intervention group
Group type: EXPERIMENTAL
Intervention: 720 mg/day of anapsos
Number of subjects: 45
Study 11196347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9195694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenwal CS3000
Number of subjects: 29
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid suspension (2.0 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid tablet (2.0 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid suspension (1.0 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid tablet (1.0 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid suspension (0.5 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisacid tablet (0.5 g)
Number of subjects: 10
Study 8008366 — intervention group
Group type: COMPARATOR
Intervention: Control (after administration of tablet or suspension)
Number of subjects: 10
Study 3051475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (2 ml/cm incision) infiltrated into the fascia
Number of subjects: 415
Study 3051475 — intervention group
Group type: COMPARATOR
Intervention: Closure without infiltration
Number of subjects: 415
Study 31222586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 70
Study 31222586 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 70
Study 28392340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36
Study 28392340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 36
Study 26165173 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Number of subjects: 29
Study 26165173 — intervention group
Group type: COMPARATOR
Intervention: Nontherapeutic Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 29
Study 23332680 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 104
Study 23332680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 21168536 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/day
Number of subjects: 207
Study 21168536 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study 18290864 — intervention group
Group type: EXPERIMENTAL
Intervention: Late hypoglycaemia (nadir of 2.2 mmol/l after 3.5 h of sleep)
Number of subjects: 16
Study 18290864 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hypoglycaemia (nadir of 2.2 mmol/l after 1 h of sleep)
Number of subjects: 16
Study 18290864 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no hypoglycaemia induced)
Number of subjects: 16
Study 16817277 — intervention group
Group type: EXPERIMENTAL
Intervention: Danshen Jueming Granules
Number of subjects: 96
Study 16817277 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang Capsules
Number of subjects: 96
Study 14622630 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 107
Study 14622630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 11152307 — intervention group
Group type: EXPERIMENTAL
Intervention: In-house IgG EIA
Number of subjects: 177
Study 11152307 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott AxSym IgG
Number of subjects: 177
Study 11152307 — intervention group
Group type: EXPERIMENTAL
Intervention: Captia Select Toxo-G
Number of subjects: 177
Study 11152307 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxreagent 'Eiken'
Number of subjects: 177
Study 11152307 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxolatex Fumouze
Number of subjects: 177
Study 11152307 — intervention group
Group type: COMPARATOR
Intervention: Sabin-Feldman dye test
Number of subjects: 177
Study 9110115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (300 mg, intravenous)
Number of subjects: 2
Study 9110115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (0.5 g bid, orally for 14 days)
Number of subjects: 2
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 5 micrograms of ISDN
Number of subjects: 16
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 15 micrograms of ISDN
Number of subjects: 16
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 60 micrograms of ISDN
Number of subjects: 16
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 240 micrograms of ISDN
Number of subjects: 16
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 1,000 micrograms of ISDN
Number of subjects: 16
Study 1530434 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received ergometrine)
Number of subjects: 16
Study 1530434 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses greater than 240 micrograms of ISDN
Number of subjects: 16
Study 4093207 — intervention group
Group type: EXPERIMENTAL
Intervention: MONOCLAIR (40 mg)
Number of subjects: 8
Study 4093207 — intervention group
Group type: COMPARATOR
Intervention: ISMO (40 mg)
Number of subjects: 8
Study 31410465 — intervention group
Group type: EXPERIMENTAL
Intervention: low SCFPns (12 g SCFPns·steer‐1·d‐1)
Number of subjects: 90
Study 31410465 — intervention group
Group type: EXPERIMENTAL
Intervention: medium SCFPns (15 g SCFPns·steer‐1·d‐1)
Number of subjects: 90
Study 31410465 — intervention group
Group type: EXPERIMENTAL
Intervention: high SCFPns (18 g SCFPns·steer‐1·d‐1)
Number of subjects: 90
Study 31410465 — intervention group
Group type: EXPERIMENTAL
Intervention: eXPC (7 g XPC·steer‐1·d‐1)
Number of subjects: 90
Study 31410465 — intervention group
Group type: EXPERIMENTAL
Intervention: ANT (330 mg monensin + 110 mg tylosin·steer‐1·d‐1)
Number of subjects: 90
Study 31410465 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 90
Study 30035583 — intervention group
Group type: EXPERIMENTAL
Intervention: Expand Your Horizon intervention (3 writing exercises focusing on body functionality)
Number of subjects: 84
Study 30035583 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 84
Study 27381275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/d
Number of subjects: 407
Study 27381275 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg/d
Number of subjects: 407
Study 24641778 — intervention group
Group type: EXPERIMENTAL
Intervention: evolutionary‐driven cognitive therapy (ED‐CT)
Number of subjects: 0
Study 24641778 — intervention group
Group type: COMPARATOR
Intervention: cognitive therapy (CT)
Number of subjects: 0
Study 22196576 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered relaxation techniques using a CD and booklet
Number of subjects: 0
Study 22196576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20453178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition classes and family YMCA membership
Number of subjects: 83
Study 20453178 — intervention group
Group type: COMPARATOR
Intervention: Nutrition classes only
Number of subjects: 83
Study 20453178 — intervention group
Group type: EXPERIMENTAL
Intervention: YMCA attendees
Number of subjects: 83
Study 20453178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonattendees
Number of subjects: 83
Study 18029326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg + Hydrochlorothiazide 12.5 mg
Number of subjects: 463
Study 18029326 — intervention group
Group type: COMPARATOR
Intervention: Zofenopril alone
Number of subjects: 463
Study 16356182 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor and tailored web-based advice
Number of subjects: 0
Study 12374437 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages of social exclusion
Number of subjects: 3
Study 12374437 — intervention group
Group type: COMPARATOR
Intervention: Predictions of future nonsocial misfortunes (accidents and injuries)
Number of subjects: 3
Study 10382332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18000
Study 10382332 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 18000
Study 10382332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 7749165 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron)
Number of subjects: 231
Study 7749165 — intervention group
Group type: COMPARATOR
Intervention: Zofran (ondansetron)
Number of subjects: 231
Study 2408179 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy using pen-injectors
Number of subjects: 30
Study 2408179 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 7332090 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg tramadol (Tramal)
Number of subjects: 50
Study 7332090 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg buprenorphine (Temgesic)
Number of subjects: 50
Study 7332090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tramadol and buprenorphine
Number of subjects: 50
Study 31604481 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched infant formula
Number of subjects: 90
Study 31604481 — intervention group
Group type: COMPARATOR
Intervention: Enteral feeding formula with different protein contents
Number of subjects: 90
Study 28259617 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cells (Group A)
Number of subjects: 35
Study 28259617 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Group B)
Number of subjects: 35
Study 25134779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive exertion (CE) - school curricular lesson
Number of subjects: 116
Study 25134779 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exertion (PE) - traditional physical education lesson
Number of subjects: 116
Study 25134779 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed cognitive and physical exertion (CPE) - coordinative physical education lesson
Number of subjects: 116
Study 23625384 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia WiLLOW intervention
Number of subjects: 168
Study 20935591 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 24046
Study 20935591 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 24046
Study 19436939 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (800 mg daily)
Number of subjects: 5212
Study 19436939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5212
Study 16924565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 40 microg four times a day
Number of subjects: 10
Study 16924565 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg two times a day
Number of subjects: 10
Study 16924565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 10